Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
UPF 648 is a potent kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor (IC50 = 20 nM). Increases kynurenic acid levels, and decreases 3-HK and QUIN levels in cerebrum and liver of neonatal rodents. Neuroprotective in a Drosophila model of Huntington's disease.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 259.09. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.86 mL||19.3 mL||38.6 mL|
|5 mM||0.77 mL||3.86 mL||7.72 mL|
|10 mM||0.39 mL||1.93 mL||3.86 mL|
|50 mM||0.08 mL||0.39 mL||0.77 mL|
References are publications that support the biological activity of the product.
Ceresoli-Borroni et al (2007) Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications. J.Neurosci.Res. 85 845 PMID: 17279543
Amaral et al (2013) Structural basis of kynurenine 3-monooxygenase inhibition. Nature 496 382 PMID: 23575632
Amori et al (2009) On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J.Neurochem. 109 316 PMID: 19226371
Campesan et al (2011) The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr.Biol. 21 961 PMID: 21636279
If you know of a relevant reference for UPF 648, please let us know.
Keywords: UPF 648, UPF 648 supplier, UPF648, potent, kynurenine, 3-monooxygenase, 3-hydroxylase, KMO, inhibitors, inhibits, huntington's, disease, KYNA, 3-hk, QUIN, neuroprotective, Hydroxylases, Kynurenine, 4926, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for UPF 648. Do you know of a great paper that uses UPF 648 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review UPF 648 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.